Biopiracy is the unauthorized taking of biological resources or traditional knowledge from indigenous communities and developing countries, typically followed by patenting and commercializing products based on that knowledge without compensation to the people who developed it. It sits at the intersection of patent law, biodiversity, and indigenous rights, and it has shaped international treaties, collapsed local economies, and generated billions in pharmaceutical revenue that never reached the communities whose knowledge made it possible.
How Biopiracy Works
The basic pattern is straightforward. A company or research institution identifies a plant, seed, or genetic resource that indigenous or local communities have used for generations. They isolate an active compound or develop a product from it, then file a patent claiming the innovation as their own. The patent grants exclusive commercial rights, effectively locking out the very people whose traditional knowledge pointed researchers to the resource in the first place.
What makes biopiracy difficult to detect and combat is that patent systems in wealthy nations historically haven’t required applicants to disclose where a biological resource came from or whether indigenous knowledge was involved. A corporation could file a patent on a use of neem oil that Indian farmers had practiced for centuries, and the patent office would have no mechanism to flag it. This gap in intellectual property law is the engine that drives biopiracy.
The Neem Tree and Rosy Periwinkle
Two cases illustrate the problem clearly. In the 1990s, a U.S. company obtained a European patent on a method of using neem tree extract as a fungicide. Neem has been used across South Asia for pest control, medicine, and agriculture for hundreds of years. An international coalition filed opposition at the European Patent Office, arguing the patent lacked novelty and inventive step, since the knowledge was already widely practiced. After years of proceedings, the patent was revoked. The case became a landmark in biopiracy advocacy, but it required enormous legal resources that most affected communities cannot afford.
The rosy periwinkle from Madagascar tells a darker story. Compounds derived from the plant were developed into two cancer drugs that proved highly effective against Hodgkin’s lymphoma and childhood leukemia. These drugs generated substantial pharmaceutical revenue. Madagascar, where the plant is native and where traditional healers had long used it medicinally, received no share of the profits. The case is one of the most cited examples of how biodiversity-rich but economically poor countries subsidize the pharmaceutical industry without compensation.
The Maca Root Crisis in Peru
Biopiracy doesn’t always involve patents filed in distant offices. Sometimes it plays out through smuggling and market disruption. Maca, a root crop grown by Andean farmers at high altitudes in Peru, became the center of a biopiracy crisis that reshaped the livelihoods of entire communities.
By the late 1990s, maca was being taken out of Peru in large quantities, eventually reaching Japan and other countries where it was cultivated and, in some cases, patented. The situation intensified in the early 2010s when buyers, primarily from China, arrived in Peru and began purchasing maca at dramatically inflated prices. Yellow maca that had previously sold for 8 to 12 soles per kilo jumped to 80 to 100 soles. Red maca hit 150 to 200 soles. Black maca reached 300 soles. Seeds were sold for 1,000 to 2,000 soles per kilo.
Local farmers saw a rare economic opportunity and sold. Many didn’t anticipate what would happen next. By 2014, Peruvian authorities were confiscating thousands of pounds of contraband maca at ports. The crop began growing in China’s Yunnan province, and when Chinese buyers returned to Peru, they no longer wanted to pay the prices they had set. Peruvian maca was “too expensive” compared to what was now being grown cheaply in China. Farmers who had taken out loans during the boom were left with debt and no market. Peru eventually banned the export of unprocessed maca and maca seeds, but the damage to local farming communities was already done.
Legal Protections and Their Limits
The main international framework addressing biopiracy is the Nagoya Protocol, which entered into force in 2014 and now has 142 ratifying parties. It establishes rules requiring that anyone accessing genetic resources from another country must get prior informed consent and negotiate fair benefit-sharing terms. In practice, enforcement has been uneven. The protocol relies on bilateral agreements between the country providing the resource and the entity using it, which gives well-resourced corporations a significant negotiating advantage.
The Hoodia case from southern Africa shows both the potential and the limits of benefit-sharing. The San people of the Kalahari had used the Hoodia plant as an appetite suppressant for generations. South Africa’s Council for Scientific and Industrial Research (CSIR) patented a compound from the plant and licensed it to a pharmaceutical company without the San’s knowledge. After the case became public and five years of negotiation followed, an agreement was reached: 6% in royalties and 8% of milestone payments from commercial activities would go to the South African San Council. Critics questioned whether even these terms were meaningful, given the layers of intermediaries and the relatively small sums likely to reach actual San communities.
India’s Digital Defense
One of the most effective countermeasures has come from India. After high-profile patent battles over turmeric and neem, the Indian government created the Traditional Knowledge Digital Library (TKDL), a database documenting traditional medicinal knowledge from ancient texts in multiple languages and patent classification formats. The goal was to create a searchable prior art resource that patent examiners worldwide could consult before granting patents.
The strategy worked. By 2011, the TKDL team had gotten more than 200 patent applications based on traditional Indian medicine withdrawn or rejected at international patent offices. Even more telling, a study found that patent applications based on Indian traditional medicine filed at the European Patent Office had declined by 44% over the same period. The database’s mere existence appeared to discourage speculative patent filings.
Digital Sequence Information: The New Frontier
Modern biotechnology has created a new challenge that existing frameworks weren’t built to handle. Advances in synthetic biology, gene editing, and artificial intelligence now allow companies to develop commercial products from digital sequence information (DSI), the genetic data of organisms uploaded to open-access databases, without ever physically accessing the biological resource. A company can download a genome sequence, synthesize the relevant compounds, and bring a product to market without setting foot in the country of origin. Traditional benefit-sharing agreements, which are triggered by physical access to a resource, become irrelevant.
The international response came in late 2024 at the UN Biodiversity Conference (COP16), where parties to the Convention on Biological Diversity adopted a new multilateral mechanism. Rather than trying to track who downloads which sequence from which country, the system decouples access from benefit-sharing. Open access to genetic data is preserved, but commercial users are expected to contribute to a global fund called the Cali Fund, officially launched in February 2025. Companies in pharmaceuticals, agricultural biotech, cosmetics, and similar sectors that exceed certain size thresholds (such as $50 million in sales or $5 million in profits) are expected to contribute 1% of their profits or 0.1% of their revenue. These funds will be distributed to biodiversity-rich countries and indigenous communities.
Researchers submitting genetic data to databases now face new requirements too: metadata must include the country of origin of the genetic resource and indicate whether traditional knowledge was used in its development.
The 2024 WIPO Patent Treaty
In May 2024, the World Intellectual Property Organization finalized a treaty that directly targets one of biopiracy’s root causes: the lack of transparency in the patent system. The treaty establishes a mandatory disclosure requirement for patent applicants worldwide. If a claimed invention is based on genetic resources or associated traditional knowledge, the applicant must disclose the country of origin and, where applicable, identify the indigenous peoples or local community that provided the knowledge.
If the applicant doesn’t know the country of origin, they must disclose the source of the resource. If they don’t know that either, they must formally declare their lack of knowledge. Patent offices are expected to provide guidance on compliance, though they have no obligation to verify whether disclosures are accurate. This is a meaningful structural change, but it places enforcement largely on the honor system, a limitation that advocates have noted.
Together, the Nagoya Protocol, India’s TKDL model, the Cali Fund, and the 2024 WIPO treaty represent an evolving patchwork of protections. They’ve made biopiracy harder to carry out invisibly, but the power imbalance between multinational corporations and indigenous communities remains the central challenge. The knowledge is worth billions. The question has always been who benefits.